At the AACR 2023 annual meeting, Dr. Lucas Rodrigues, Head of Veterinary Research at FidoCure®, presented the results of two innovative studies which demonstrated the power of real-world data from dogs with cancer to drive drug development strategies and inform human clinical trials.
The first study, titled "High frequency of TP53 mutations in canine skin tumors recapitulates solar induced human lesions representing an important research model of spontaneous diseases," focused on the similarities between skin tumors in dogs and humans caused by sun exposure. The study found a high frequency of TP53 mutations in canine skin tumors, mirroring those seen in humans with solar-induced skin lesions. This validates the use of dogs as a valuable research model for spontaneous diseases.
The second study, titled “Use of real-world data of dogs with cancer to drive drug development strategy and inform human clinical trials”, was very well received by the audience. This study highlighted the importance of data-driven decision making in drug development and clinical trial design. The research showed that leveraging real-world data of dogs with cancer can lead to faster and more cost-effective drug development strategies and more accurate clinical trial designs. This can greatly speed up the process of drug development and implementation.
As Dr. Lucas Rodrigues presented the results of these two groundbreaking studies at the AACR 2023 annual meeting, it became increasingly clear that FidoCure® is at the cutting edge of harnessing the power of real-world data to drive cancer research and drug development. In doing so, FidoCure® is paving the way for a new era of cancer research that is more patient-centric, with the aim of improving outcomes for both humans and our canine companions.
Our studies are opening the door to a new, powerful approach in developing cancer treatments and can help to bridge the gap between treating animals and humans.
